Evolve to Present at NEC Symposium 2017
Evolve BioSystems is pleased to announce that Dr. Steven Frese, Associate Director of R&D, will be presenting at the Necrotizing Enterocolitis (NEC) Symposium 2017, held at UC Davis April 5-7 2017.
The NEC Symposium: A Transdisciplinary Approach to Improved Outcomes, will be cohosted by the NEC Society and UC Davis, and is the first national conference to bring together leading clinicians, researchers, parent advocates and others involved in the study of neonatal NEC.
Dr. Frese's presentation, titled "The infant gut symbiont, Bifidobacterium longum subsp. infantis EVC001, restores ecosystem function in breastfed infants," will discuss the role of the infant gut microbiome with respect to the prevention of NEC.
For more details on the NEC Symposium, visit: www.necsociety.org
To learn more about Evolve BioSystems, visit: www.evolvebiosystems.com
Tracy Shafizadeh, PhD
Director, Scientific Communications
About Evolve BioSystems
Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy human gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve’s discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well as in various animal species. Evolve completed a $9 million Series A capital raise in 2015 and has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering. In addition, Evolve is undertaking further clinical studies to build out its offering of microbiome-based solutions across a spectrum of unmet clinical needs.